NEW YORK, NY / ACCESSWIRE / August 27, 2020 / PAVmed Inc. (NASDAQ:PAVM)(NASDAQ:PAVMZ) (the "Company" or "PAVmed"), a highly differentiated, multi-product, commercial-stage medical device company, today announced that it will be presenting at the LD 500 investor conference on Thursday, September 3, 2020 at 7:20 a.m. PST / 10:20 a.m. EST. Lishan Aklog, M.D., Chairman and Chief Executive Officer of the Company, will be presenting a corporate overview to a live audience.

Register here: https://ld-micro-conference.events.issuerdirect.com/

"We have been waiting for this moment all year long. Due to COVID, it has been nearly impossible for physical conferences to even take place. I want to show the world that you can still learn, have a great time, and see some of the most unique companies in the capital markets today. All without having to step foot outside. For the first time, LD Micro is accessible to everyone, and we are honored to welcome you to one of the most trusted platforms in the space," stated Chris Lahiji, Founder of LD.

The LD 500 will take place on September 1st through the 4th.

View PAVmed's profile here: http://www.ldmicro.com/profile/PAVM

Profiles powered by LD Micro – News Compliments of Accesswire

About PAVmed

PAVmed Inc. is a highly differentiated, multi-product, commercial-stage medical device company employing a unique business model designed to advance innovative products to commercialization rapidly and with less capital than the typical medical device company. This proprietary model enables PAVmed to pursue an expanding pipeline strategy with a view to enhancing and accelerating value creation while seeking to further expand its pipeline through relationships with its network of clinician innovators at leading academic centers. PAVmed's diversified product pipeline addresses unmet clinical needs encompassing a broad spectrum of clinical areas with attractive regulatory pathways and market opportunities. Its four operating divisions include GI Health (EsoGuard™ Esophageal DNA Test, EsoCheck™ Esophageal Cell Collection Device, and EsoCure™ Esophageal Ablation Device with Caldus™ Technology), Minimally Invasive Interventions (CarpX™ Minimally Invasive Device for Carpal Tunnel Syndrome), Infusion Therapy (PortIO™ Implantable Intraosseus Vascular Access Device and NextFlo™ Highly Accurate Disposable Intravenous Infusion Set), and Emerging Innovations (non-invasive laser-based glucose monitoring, pediatric ear tubes and mechanical circulatory support). For more information, please visit www.pavmed.com, follow us on Twitter, connect with us on LinkedIn, and watch our videos on YouTube. For more information on our majority owned subsidiary, Lucid Diagnostics Inc., please visit www.luciddx.com, follow Lucid on Twitter, and connect with Lucid on LinkedIn.

About LD Micro

Back in 2006, LD Micro began with the sole purpose of being an independent resource to the microcap world.

What started as a newsletter highlighting unique companies, has transformed into the pre-eminent event platform in the space.

The upcoming "500" in September is the Company's most ambitious project yet, and the first event that is accessible to everyone.

For those interested in attending, please contact David Scher at david@ldmicro.com or visit www.ldmicro.com for more information.

Contacts:

Investors
Mike Havrilla
Director of Investor Relations
(814) 241-4138
JMH@PAVmed.com

Media
Shaun O'Neil
Chief Commercial Officer
(518) 812-3087
SMO@PAVmed.com

SOURCE: PAVmed, Inc. via LD Micro

ReleaseID: 602758

TEL AVIV, ISRAEL / ACCESSWIRE / August 27, 2020 / Owlytics announced today, August 27, 2020, in Tel Aviv that the company has entered into a definitive service agreement with a global pharma vendor. The service will provide continuous motion and physiological personal functionality monitoring of Neurology disease patients, as part of a multi-site clinical study conducted in the US, Europe, and additional sites.

According to Gill Zaphrir, the company's Co-Founder and CEO, "Owlytics' all remote, cellular-based senior risk monitoring solution will now be adapted to monitor people with neurological diseases, with the input and cooperation of clinical researchers at the Tel Aviv Medical Center".

The company's personal wearable-based AI system is aimed at providing seniors with safety, independence, and better health. It is designed to continuously and automatically detect falls, assess fall risk, and provide early warning of potential health deterioration, including sleep, sleep interruptions, and alterations in daily-living physical activity patterns. Based on sophisticated AI algorithms, the system delivers actionable outcomes that help provide better senior and outpatient care while reducing healthcare costs.

All remote: Owlytics monitors and protects users anywhere, with no infrastructure needed, just by having the users wear a cellular-enabled Samsung Active 2 SmartWatch. Installation and service are managed remotely as well.

Owlytics currently provides services to senior living facilities and elderly home care clients in the US and Israel. Owlytics has won an Israeli Health Ministry RFP and 2 innovation grants from the Israeli Innovation Authority for the prevention and detection of falls. They are supported by Prof. Jeff Hausdorff and his research team at the Center for the Study of Movement, Cognition and Mobility in the Neurological Institute at Tel Aviv Sourasky Medical. Together they are advancing a clinical study to augment the real-time assessment and prediction of fall risk by evaluating missteps and near falls in addition to other metrics. The two parties have also entered into a new remote monitoring collaboration to bring the Owlytics AI and wearable-sensor approach into the study and care of people with neurological diseases like Multiple Sclerosis.

About Owlytics

Owlytics is a rapidly growing company dedicated to elevating the lives of all seniors by combining continuous personal monitoring with the predictive power of data analytics. We developed a continuous, AI-based monitoring solution that collects, analyzes and reports personal health data in order to administer preventative solutions in real time. We are focused on providing innovative, remote patient monitoring systems for independent and assisted living facilities, home care agencies and other services where a higher level of personal care and safety are valued. Owlytics helps increase the quality of care and safety for all residents while decreasing the costs of care. For more information please visit https://www.owlytics.com/.

Contact for Owlytics

Gill Zaphrir
Co-Founder and CEO
Owlytics Healthcare
M 972-54-445-6106
Gill@owlytics.com
www.owlytics.com

SOURCE: Owlytics Healthcare

ReleaseID: 603604

SINGAPORE / ACCESSWIRE / August 27, 2020 / Decentralized data network Bluzelle has released details of a new oracle intended to enhance security for DeFi projects as well as to interact with fully decentralized databases. The decentralized Bluzelle Oracle will also provide valuable infrastructure in the form of a high-demand price feed for DeFi applications, such as those concerned with payments, lending and staking.

Anchored by the BluzelleDB database and its hundreds of validator nodes, the Bluzelle Oracle represents much-needed scalability and security for the rapidly growing DeFi space, with protocols having recently surpassed the $6 billion threshold for value locked. BluzelleDB helps projects store dApp data in a decentralized manner.

Bluzelle's Decentralized Oracles are uniquely able to interact fully decentralized databases. Within its DeFi functionality, Bluzelle's oracle solution enables historical prices to be stored and referenced, with three principal benefits introduced: access to trustworthy price feeds validated by hundreds of nodes; the ability to run statistical analysis to safeguard against attacks, enabled by access to a history of data points; and fast retrieval of prices, since they are pre-stored on BluzelleDB.

"DeFi is now at over $6.7B total value locked and shows no signs of slowing down," said Bluzelle CTO Neeraj Murarka. "This invites more attackers and thieves. Bluzelle Oracles has a unique algorithm to determine accurate asset prices and at the same time provide advanced warnings of threats on the DeFi app.

"Having built the Bluzelle database infrastructure the past two years, this was a natural extension of our offering."

Further information can be found at bluzelle.com. A discord channel for DeFi dApps enables interested parties to be directly connected with the team and added to the early list of service users.

About Bluzelle

Powered by a Byzantine fault-tolerant cluster of blockchains customized specifically for database operations, Bluzelle is a decentralized database for Web3. Its advanced data delivery network promises to protect businesses from data breaches, network failures and performance troubles. Bluzelle effectively serves as an "Airbnb of databases," with developers paying for storage space and read/write to the decentralized database. While data storage is the foundation, Bluzelle is in the process of developing data feeds and oracles for the next phase of its evolution to help bring about a faster and more secure internet.

For more information please visit: www.bluzelle.com

Contact for Bluzelle:

Dan Edelstein
Dan@marketacross.com
+972-545-464-238

SOURCE: Bluzelle

ReleaseID: 603602

Food preservative manufacturers are turning their focus clean label food trends to combat growing consumer hesitation towards foods with conventional preservative formulations.

ROCKVILLE, MD / ACCESSWIRE / August 27, 2020 / The global food preservatives market is expected to hit a US$ 2.5 billion valuation between the assessment years from 2020 to 2030. The coronavirus pandemic is expected to have a marginal impact on the food preservatives market. Growing consumer health consciousness has reduced demand for commercial foods with synthetic preservatives. However, growth in consumption of convenience foods is likely to generate growth opportunities particularly for natural alternatives.

"Consumers are increasingly preferring ready-to-eat foods instead of home preparations owing to hectic lifestyles. Such foods comprise various preservatives to boost quality and minimize waste from microbial activity, which will contribute to demand for food preservatives in the years ahead," says the FACT.MR analyst.

Request a sample of the report to gain more market insights at

https://www.factmr.com/connectus/sample?flag=S&rep_id=2250

Food Preservatives Market- Key Takeaways

Sodium propionate anti-microbial food preservatives contribute significantly to revenues with high demand for bakery and confectionary applications.
Natural and organic food preservative formulations are reflecting fast growth, supported by regulatory acceptance and clean label trends.
Asia Pacific is displaying rapid growth in food preservative adoption supported by demand for ready-to-eat foods, and the expansion of working populations.

Food Preservatives Market- Driving Factors

Growing international food trade is a key factor contributing to the use of food preservatives.
Safety and hygiene regulations governing the food industry contribute to preservative sales.

Food Preservatives Market- Major Restraints

Growing consumer bias against synthetic food preservatives, owing to potential health risks hurts sales.
Preservative free food processing methods are gradually gaining traction and holding back market demand.

COVID-19 Impact on Food Preservatives Market

The coronavirus pandemic has had a marginal impact on the food preservatives industry. The growth in health consciousness among consumers is a major factor hindering the adoption of synthetic food preservatives during this period. On the other hand, demand for processed convenience food has remained strong during the crisis, which provides opportunities for preservative manufacturers to capitalize on. Natural and organic preservatives are expected to make major inroads, and demand is likely to remain strong even after the end of the pandemic.

Explore the global food preservatives market with 170 figures, 92 data tables, along with the table of contents of the report. You can also find detailed segmentation on https://www.factmr.com/report/2250/food-preservative-market

Competitive Landscape

BASF SE, Chr. Hansen Holding A/S, Corbion N.V., and Cargill Inc. are some of the leading food preservative manufacturers in the global market.

Food preservatives manufacturers are primarily invested in product innovations and portfolio expansion incorporating natural and clean label trends to meet evolving needs of the food & beverage industry.

For instance, Lycored has unveiled tomato-based colors which can be used in milk products for not only aesthetics, but also to increase product stability in varying retail environments. Niacet has introduced Provian Plus a dry vinegar-based food preservative aimed towards plat-based meat alternatives. Corbion has announced a new strategy for investments into lactic acid and natural food preservation through 2025.

About the Report

This study offers readers a comprehensive market forecast of the food preservatives market. Global, regional and country-level analysis of the top industry trends impacting the food preservatives market is covered in this FACT.MR study. The report offers insights on the food preservatives market on the basis of product (natural and synthetic), function (antimicrobial, antioxidant, and others), and application (bakery & processed food, beverages, dairy & milk products, meat, poultry & seafood), across six regions (North America, Latin America, Europe, East Asia, South Asia & Oceania, and Middle East & Africa).

Explore FACT.MR's Comprehensive Coverage of Food & Beverages Landscape

Propionic Acid Market– Get the latest insights on the global propionic acid market through FACT.MR's report covering analysis for projection period (2018-2028).

Flavor Enhancer Market– FACT.MR's study on the global flavor enhancer market covers trends, tech innovations, players, and strategies for 2018-2028.

Color Preservatives Market– Obtain analysis on the global color preservatives market through FACT.MR's latest report covering competitive analysis, key regions, along with segmental analysis for 2019-2029.

About Fact.MR

Expert analysis, actionable insights, and strategic recommendations of the veteran research team at FACT.MR helps clients from across the globe with their unique business intelligence requirements. With a repository of over a thousand reports and 1 million+ data points, the team has scrutinized the food and beverages sector across 50+ countries for over a decade. The team provides unmatched end-to-end research and consulting services.

Contact:

Fact.MR
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Email: sales@factmr.com
Web: https://www.factmr.com/
PR- https://www.factmr.com/media-release/1590/global-food-preservative-market

SOURCE: Fact.MR

ReleaseID: 603603

SEATTLE, WA / ACCESSWIRE / August 27, 2020 / GRN Holding Corporation, (OTC PINK:GRNF)(the "Company"), announces its filing of Form 8-K August 26, 2020, disclosing important corporate actions designed to facilitate its acquisition plans. On November 12, 2019, the Company announced its acquisition strategy by disclosing its execution of several non-binding Letters of Intent to acquire several businesses. Beginning January, 2020, the Company began its due diligence into these acquisition targets, and proceeded to execute binding letters of intent to move forward with the acquisition process, with the next step entering into material definitive agreements to formally complete the acquisitions.

Justin Costello, Company Chief Executive Officer and Director, commented: "In analyzing the capital structure of our company, in conjunction with our asset strategy, it was clear that in order to complete our acquisitions, the Company required flexibility to issue restricted shares as consideration. As we disclosed in our recent annual report filed with the SEC, our authorized shares are limited to 250 million shares and as of today, the Company has issued 249,843,977 shares. Obviously, and in order to complete the acquisitions, the Company determined to increase its authorized shares to accommodate our acquisition strategy in order to bring value to our shareholders.

About GRN Hold Corporation

GRN Holding Corporation (OTC PINK:GRNF) is a Nevada registered publicly-traded company.

For more information, please contact:

Justin Costello
IR@grnholding.com

Forward-looking Statements

This news release contains "forward-looking statements" which are not purely historical and may include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities and words such as "anticipate," "seek," intend," "believe," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects, the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based products. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-k, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission. For more information, please visit www.sec.gov.

SOURCE: GRN Holding Corporation

ReleaseID: 603613

NEW YORK, NY / ACCESSWIRE / August 27, 2020 / Newswire has helped thousands of customers distribute important news and information across the wire and their comprehensive distribution network. Despite the turmoil and uncertainty, the pandemic has unleashed globally, C-suite executives and business leaders have the obligation to ensure the sustainability of the companies they serve.

For the past year, Newswire has empowered many of its customers with the Earned Media Advantage. According to the company, the Earned Media Advantage is the result of an integrated media and marketing communications strategy that has helped position many of its top customers on coveted media placements on outlets such as Dallas Business Journal, Bloomberg, Business Insider, and NBC News.

"Having the ability to communicate early and often provides the foundation for greater success with your media and marketing communications. The Earned Media Advantage Guided Tour was developed to specifically address both sides of the house to increase your market presence and increase sales opportunities amid this turbulent business climate," said Charlie Terenzio, Vice President of Earned Media Advantage Business Unit. "We have seen increased sales as a by-product of consistent media and marketing campaigns. In fact, we have seen the best ROI when companies start thinking strategically long term."

"We understand that companies need to demonstrate their resilience and leadership during this crisis. Our expert team helps Guided Tour customers navigate the news cycle and effectively implement their custom communications strategy. At the same time, they can also lower their customer acquisition costs," said Terenzio.

Following its successful track record of the Earned Media Advantage Guided Tour, Newswire recently announced the expansion of the program with two new offerings: Market Builder and Sales Accelerator. Newswire's EMA GT Market Builder + Sales Accelerator is the industry's only solution on the market for companies looking to augment their sales growth through optimized media and marketing communications campaigns.

By prioritizing lead generation and applying a layered approach with consistent marketing campaigns, brands can focus their content distribution to position the brand as a thought leader and increase sales opportunities with prospective customers.

If you are interested in learning more about how Newswire's Earned Media Advantage Guided Tour Market Builder + Sales Accelerator, please navigate to the official program page for more information.

About Newswire​

Newswire delivers press release and multimedia distribution software and services (SaaS) that empower the Earned Media Advantage: greater brand awareness, increased traffic, greater return on media and marketing communications spend, and the competitive edge. With over a decade of experience, Newswire continues to provide its customers with the ability to deliver the right message to the right audience at the right time through the right medium.​

To learn more about how Newswire can help you, visit http://www.newswire.com.

Contact Information

Charlie Terenzio
VP of Earned Media Advantage Business
Newswire
Office: 813-480-3766
Email: charlie@newswire.com

Related Images

SOURCE: Newswire

ReleaseID: 603461

OCALA, FL / ACCESSWIRE / August 27, 2020 / AIM ImmunoTech Inc. (NYSE American:AIM) is pleased to announce that it has identified an effective in vitro model at The Institute for Antiviral Research at Utah State University for testing Ampligen, a dsRNA TLR3 agonist, and the results show that Ampligen was able to decrease SARS-CoV-2 infectious viral yields by 90% at clinically achievable intranasal Ampligen dosage levels. This result supports AIM's goal of developing an intranasal prophylactic approach using Ampligen to prevent COVID-19.

"We are pleased with these results, as they establish Ampligen's bio-activity against SARS-CoV-2 as well as support our decision to test Ampligen in humans as an intranasal prophylaxis and early-onset therapy against COVID-19," said AIM CEO Thomas K. Equels.

The 3D-mucociliary tissue culture of normal, human-derived tracheal/bronchial epithelial cells sufficiently models some of the key innate immune responses needed to demonstrate Ampligen's prophylactic effect on SARS-CoV-2, the virus that causes COVID-19. The 90% effective concentration (EC90) of Ampligen observed in this tissue culture model is clinically achievable in human subjects to presumptively decrease SARS-CoV-2. Currently, there is a lack of an adequate animal model and therefore the company utilized the USA-WA1/2020 strain of SARS-CoV-2 in a 3-D, in vitro model of normal, human-derived tracheal/bronchial epithelial cells. The results show that Ampligen was able to decrease SARS-CoV-2 infectious viral yields by 90% at clinically achievable intranasal Ampligen dosage levels. This result supports AIM's goal of developing an intranasal prophylactic approach using Ampligen to prevent COVID-19.

Ampligen is believed to be a powerful positive modulator of human innate immunity and therefore the best measure of efficacy will be obtained in animal and human experimentation utilizing a living, in vivo, innate immune system.

In a brief recap of AIM's experimental history in SARS-like diseases, Ampligen has demonstrated clear activity in prior SARS-CoV-1 virus animal experiments. With a SARS-CoV-1 virus mouse model, Ampligen demonstrated 100% protective survival benefit compared to 100% mortality in a saline control group. Ampligen also reduced SARS-CoV-1 lung titers to below the level of detection (Day 2009 and Barnard 2006). However, because similar animal models with mice designed to replicate the human response to SARS-CoV-2 are not yet readily available for experimentation, AIM sought an in vitro experimental model. However, as previously disclosed, the typical cell line for viral experimentation, cloned AGM cells, have lost the genetic capacity to allow Ampligen's biomechanics to be expressed. This general effect was first observed and reported in 2006 in Table 1 of the Barnard, et al. publication in Antiviral Chemistry and Chemotherapy 2006, 17:275. See also, (https://dd7pmep5szm19.cloudfront.net/2265/0001493152-20-011683.htm)

In 2006, recognizing this defect in the in vitro model, Barnard, et al. then used an in vivo mouse model and Ampligen showed high antiviral activity with reduction in lung titers of SARS-CoV-1 to below the level of detection. Then, in a 2009 follow-up animal experiment, Ampligen demonstrated 100% protective survival as compared to 100% mortality in the control group of rodents.

For these reasons, while awaiting the availability of future in vivo animal experimental data and human clinical data, AIM pursued this more relevant in vitro model to demonstrate Ampligen's positive bioactivity against the virus that causes COVID-19 using a model consisting of normal, human-derived tracheal/bronchial epithelial (TBE) cells which have been cultured to form a multi-layered, highly differentiated model that closely resembles the epithelial tissue of the respiratory tract. These cells still retained both toll-like receptors as well as the ability to produce and react to interferons induced by Ampligen.

This demonstration of Ampligen's bioactivity against SARS-CoV-2, resulting in a significant in vitro reduction of infectious virus at clinically achievable doses confirms our commitment for the development of Ampligen as both a prophylaxis and early onset intranasal therapy for COVID-19.

About AIM ImmunoTech Inc.
AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat immune disorders, viral diseases and multiple types of cancers. AIM's flagship products include the Argentina-approved drug rintatolimod (trade names Ampligen® or Rintamod®) and the FDA-approved drug Alferon N Injection®. Based on results of published, peer-reviewed pre-clinical studies and clinical trials, AIM believes that Ampligen® may have broad-spectrum anti-viral and anti-cancer properties. Clinical trials of Ampligen® include studies of cancer patients with renal cell carcinoma, malignant melanoma, colorectal cancer, advanced recurrent ovarian cancer and triple negative metastatic breast cancer. These and other potential uses will require additional clinical trials to confirm the safety and effectiveness data necessary to support regulatory approval and additional funding. Rintatolimod is a double-stranded RNA being developed for globally important debilitating diseases and disorders of the immune system.

Cautionary Statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act (PSLRA) of 1995. Words such as "may," "will," "expect," "plan," "anticipate" and similar expressions (as well as other words or expressions referencing future events or circumstances) are intended to identify forward-looking statements. Many of these forward-looking statements involve a number of risks and uncertainties. Among other things, for those statements, we claim the protection of safe harbor for forward-looking statements contained in the PSLRA. We do not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. For example, significant additional testing and trials will be required to determine whether Ampligen will be effective in the treatment of COVID-19 in humans and no assurance can be given that it will be the case. Results obtained in animal models and in vitro testing do not necessarily predict results in humans or ultimate FDA approval. Human clinical trials will be necessary to prove whether or not Ampligen will be efficacious in humans. No assurance can be given as to whether current or planned immuno-oncology clinical trials will be successful or yield favorable data and the trials are subject to many factors including lack of regulatory approval(s), lack of study drug, or a change in priorities at the institutions sponsoring other trials. In addition, initiation of planned clinical trials may not occur secondary to many factors including lack of regulatory approval(s) or lack of study drug. Even if these clinical trials are initiated, the Company cannot assure that the clinical studies will be successful or yield any useful data or require additional funding. Some of the world's largest pharmaceutical companies and medical institutions are racing to find a treatment for COVID-19. Even if Ampligen proves effective in combating the virus, no assurance can be given that our actions toward proving this will be given first priority or that another treatment that eventually proves capable will not make our efforts ultimately unproductive. We recognize that all cancer centers, like all medical facilities, must make the pandemic their priority. Therefore, there is the potential for delays in clinical trial enrollment and reporting in ongoing studies in cancer patients because of the COVID-19 medical emergency. No assurance can be given that future studies will not result in findings that are different from those reported in the studies referenced. Operating in foreign countries carries with it a number of risks, including potential difficulties in enforcing intellectual property rights. We cannot assure that our potential foreign operations will not be adversely affected by these risks.

CONTACT:
Crescendo Communications, LLC
Phone: 212-671-1021
Email: aim@crescendo-ir.com

AIM ImmunoTech Inc
Phone: 800-778-4042
Email: IR@aimimmuno.com

SOURCE: AIM ImmunoTech Inc.

ReleaseID: 603567

PALO ALTO, CA and TORONTO / ACCESSWIRE / August 27, 2020 / Inpixon (NASDAQ:INPX), a leading indoor data company that delivers Indoor Intelligence™ solutions, today announced that it will be presenting at The LD 500 Investor conference being held virtually on September 1-4, 2020. The LD 500 will feature the most prominent companies in the small and micro-cap world, alongside interviews and keynotes with thought leaders from various industries.

View Inpixon's LD Micro profile here: https://www.ldmicro.com/profile/INPX

Nadir Ali, Chief Executive Officer of Inpixon, is scheduled present on Wednesday, September 2nd at 2:00 p.m., Eastern Time. The presentation will be webcast live on the conference event platform, which can be accessed here. One-on-one meetings will be held throughout the conference via video conference calls.

To schedule a one-on-one meeting with Inpixon, you may submit your request online via the link provided upon registration or email your request to wade@ldmicro.com. To register for the conference, contact David Scher at david@ldmicro.com or visit https://ld-micro-conference.events.issuerdirect.com/.

Profiles powered by LD Micro – News Compliments of Accesswire

About LD Micro

Back in 2006, LD Micro began with the sole purpose of being an independent resource to the microcap world. What started as a newsletter highlighting unique companies, has transformed into the pre-eminent event platform in the space. The upcoming "500" in September is the Company's most ambitious project yet, and the first event that is accessible to everyone.

About Inpixon

Inpixon® (Nasdaq: INPX) is the Indoor Intelligence™ company that specializes in capturing, interpreting and giving context to indoor data so it can be translated into actionable intelligence. The company's Indoor Intelligence platform ingests diverse data from IoT, third-party and proprietary sensors designed to detect and position active cellular, Wi-Fi, UWB and Bluetooth devices. Paired with a high-performance data analytics engine, patented algorithms, and advanced mapping technology, Inpixon's solutions are leveraged by a multitude of industries to do good with indoor data. This multidisciplinary depiction of indoor data enables users to increase revenue, decrease costs, and enhance safety. Inpixon customers can boldly take advantage of location awareness, analytics, sensor fusion and the Internet of Things (IoT) to uncover the untold stories of the indoors. For the latest insights, follow Inpixon on LinkedIn, Twitter, and visit inpixon.com.

Inpixon Contacts

Media relations and general inquiries:
Inpixon
Email: marketing@inpixon.com
Web: inpixon.com/contact-us

Investor relations:
Crescendo Communications, LLC
Tel: +1 212-671-1020
Email: INPX@crescendo-ir.com

SOURCE: Inpixon via LD Micro

ReleaseID: 603536

Thioglycolate manufacturers are leveraging the demand for processed foods during the covid-19 pandemic to sustain limited sales operations for the duration of the crisis.

DUBAI, UAE / ACCESSWIRE / August 27, 2020 / The thioglycolates market is anticipated to hit a valuation of US$ 137.7 Mn by the end of the forecast period between 2019 and 2029. The coronavirus outbreak has largely been negatively influencing the thioglycolates market. Reduced demand for cosmetics and personal care products coupled with the fall in oil & gas industry activities will hurt short term prospects. Recovery is likely to be gradual in 2021 owing to market economic uncertainties.

"Research initiatives to boost innovation in the manufacturing sector products with minimal health side effects, to meet evolving consumer needs generates key growth opportunities for market players in years to come. The growth of the cosmetics industry in emerging economies will also be beneficial to market developments," says the FMI study.

Request a report sample to gain comprehensive market insights at https://www.futuremarketinsights.com/reports/sample/rep-gb-11223

Thioglycolates Market – Important Takeaways

Straightening and coloring cosmetic product applications are witnessing strong growth owing to superior efficacy in hair volume building processes.
Potassium thioglycolate is finding increased use in frozen food applications as a preservative owing to anti-microbial characteristics.
Asia Pacific and Latin America are displaying positive growth prospects owing to urbanization and associated changes in consumer biases.

Thioglycolates Market – Driving Factors

Growth of urban populations and the resultant demand for cosmetics and frozen foods remains a major driver for market growth.
Growing scope of applications including agrochemicals, leather processing, and corrosion inhibition for oil industry supports market growth.

Thioglycolates Market – Leading Constraints

Strict regulations associated to production and handling of thioglycolates challenges market growth.
Toxicity and health hazards from thioglycolates hinder global adoption and application rates.

Expected Impact on Market by Coronavirus Outbreak

The coronavirus pandemic is expected to have short term negative impact on the thioglycolate market. Significant drop in the demand and sales of cosmetics and personal care products, coupled with the slump in the oil and gas industry hurts demand in the short term. Lockdown measures on industrial activity and international trade will also hurt market growth. On the other hand, growing demand for convenience foods and frozen foods during the pandemic will provide niche growth opportunities, which can be leveraged by manufacturers to lower their losses during this period.

For information on the Research Approach used in the Report, Request Methodology@ https://www.futuremarketinsights.com/askus/rep-gb-11223

Competition Landscape

Some of the leading players participating in the Thioglycolates market are ICC Chemical Corp., American International Chemical Inc., Bruno Bock Chemische Fabrik KG, Haihang Industry Co. Ltd., Advanced Technology & Industrial Co. Ltd., CellMark Chemicals, AN Pharma Tech Co. Ltd., and Alfa Aesar.

Players in the Thioglycolates market are investing in broadening the scope of application for their offerings, widening the portfolio and customizing solutions as per end use industry.

For instance, Arkema has unveiled thioglycolate formulation for hydrocarbon stimulation applications in dolomite formation. Miles Chemical Company has introduced 80% thioglycolic acid facility in California for nutrition applications. Robinson Brothers are providing a 45% aqueous sodium thioglycolate solution for depilatory creams and foams cosmetic applications.

Buy Now@ https://www.futuremarketinsights.com/checkout/11223

More on the Report

FMI provides in-depth insights on the Thioglycolate market. The market is segmented in terms of product type (methanol, ethylene glycol, diesel, naphthalene, ethylbenzene, and formaldehyde), and application (haircare and cosmetics, chemical intermediate, and pharmaceuticals), across seven regions (North America, Latin America, Europe, East Asia, South Asia, Oceania, and MEA).

Explore Coverage of FMI's Food & Beverages Landscape

GCC Functional Food Market: Find insights on the GCC functional food market with analysis of statistics, segments, players, influencers, and business strategies adopted over a 6-year forecast period.

Natural Food Colors Market: FMI's report on the natural food colors market provides insights on the market during 2018-2028. The study evaluates restraining forces, revenue sources, market leaders, and strategies.

Stevia Market: An analysis on the stevia market with data on opportunities, growth levers, regional markets, restraints, regulatory policies, and strengths of market leaders.

About FMI

Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in London, the global financial capital, and has delivery centers in the U.S. and India. FMI's latest market research reports and industry analysis help businesses navigate challenges and make critical decisions with confidence and clarity amidst breakneck competition. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. A team of expert-led analysts at FMI continuously tracks emerging trends and events in a broad range of industries to ensure that our clients prepare for the evolving needs of their consumers.

Contact

Mr. Abhishek Budholiya
Unit No: AU-01-H Gold Tower (AU), Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
MARKET ACCESS DMCC Initiative
For Sales Enquiries: sales@futuremarketinsights.com
For Media Enquiries: press@futuremarketinsights.com

Report: https://www.futuremarketinsights.com/reports/thioglycolates-market
Press Release Source: https://www.futuremarketinsights.com/press-release/thioglycolates-market

SOURCE: Future Market Insights

ReleaseID: 603599